A stimulant smart pill used to treat narcolepsy and other sleep disorders. Studies have shown that it also improves alertness and cognitive function in healthy individuals.
Several studies have found that Armodafinil can help improve patients’ results after traumatic brain injury. However, the results are mixed and additional trials need to be done using larger sample sizes.
1. Increased alertness
Patients’ outcomes following traumatic brain injury have been reported to be improved by Modvigil 200mg (TBI). It is an effective treatment for sleepiness and can reduce fatigue, increase attention, and improve memory.
The medication can also be used to treat fatigue after a stroke. Studies have shown that it can help reduce the amount of time patients spend in an ICU or hospital, as well as reduce the length of mechanical ventilation, tracheostomies, and medical costs associated with TBI.
In one study, Menn et al1 tested the effectiveness of modafinil for treating excessive sleepiness in patients with TBI. They found that patients using modafinil improved their sleep latency (assessed by the Modified Sullivan Test [MSLT] score) and reported a significant improvement in wakefulness (assessed by the Clinical Global Impression of Change [CGI-C] scale).
2. Reduced fatigue
Fatigue is one of the most common and difficult symptoms to manage following a traumatic brain injury. This problem can significantly impact an individual’s quality of life and interfere with rehabilitation outcomes.
The causes of fatigue are still unclear. Some researchers suggest it is related to an increase in mental effort required to perform cognitive tasks, while others believe it is linked to neuro-inflammation or psychological processes.
Other research suggests that it may be a function of brain structures that are not functioning normally after a TBI. For example, a study found that the medial prefrontal cortex (PFC), which is part of the reward circuitry in the brain, was not working as it should after mTBI.
Some studies have shown that Buy Artvigil Online can help reduce patients’ fatigue and fatigue-related sleepiness after traumatic brain injury. These results were obtained from randomized, placebo-controlled trials. These RCTs included patients with Parkinson’s disease, multiple sclerosis, and TBI.
3. Improved memory
A traumatic brain injury (TBI) occurs when the head is hit by an external force. This impact can cause severe, immediate damage to the brain or result in secondary injuries that develop gradually over hours, days, or weeks after the injury.
This can lead to a condition known as chronic traumatic encephalopathy, which causes memory problems and other cognitive issues. This condition is caused by repetitive head injuries and is not something that typically affects children or infants.
Several smart pills have been shown to have the ability to improve memory after brain injury, including Modafinil. These medications work by improving the enlargement of motor-evoked potentials, reducing intracortical inhibition, and promoting the influx of neurotransmitters like dopamine and GABAergic systems into the brain.
This medication may be used in conjunction with other therapies such as cognitive rehabilitation therapy. These programs are tailored to each individual and may involve specialized exercises, games, and other brain training activities.
4. Increased motivation
Armodafinil may increase the motivation of patients to participate in neurorehabilitation programs. This is because it has the potential to accelerate the brain’s ability to reorganize itself and restore its lost neurological function.
This is especially true in the case of patients who have suffered a traumatic brain injury. This type of injury is characterized by a wide range of symptoms, including a decreased level of consciousness, psychiatric sequelae, and neurocognitive sequelae.
Several studies have examined the effectiveness of Armodafinil in patients with traumatic brain injury (TBI). One study, by Jha et al21, was a randomized, double-blind, placebo-controlled trial of 51 subjects who were at least 1-year post-TBI and had fatigue or EDS using the Fatigue Severity Scale (FSS) and the Energy Severity Score (ESS).
This randomized, controlled trial found no difference between Armodafinil and placebo for FSS scores at Weeks 4 and 10. However, Armodafinil was effective for ESS scores. Despite these findings, the authors concluded that additional trials with larger sample sizes and longer treatment periods are needed before making a proper recommendation about Armodafinil use in TBI patients.
